Real-life prescribing of asthmatic treatments in UK general practice over time using 2014 BTS/SIGN steps.
Journal
NPJ primary care respiratory medicine
ISSN: 2055-1010
Titre abrégé: NPJ Prim Care Respir Med
Pays: England
ID NLM: 101631999
Informations de publication
Date de publication:
11 07 2019
11 07 2019
Historique:
received:
10
12
2018
accepted:
30
05
2019
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
20
9
2020
Statut:
epublish
Résumé
The 2014 British Thoracic Society (BTS) and Scottish Intercollegiate Guideline Network (SIGN) guidelines recommend a stepwise approach to asthma management. We investigated the management of asthma in primary care in the UK to understand how real-world practice compares with BTS/SIGN guidelines. Asthma patients were identified from the UK Clinical Practice Research Datalink from September 2006 to August 2016. Aims were to classify patients according to BTS/SIGN steps, describe the proportion of patients transitioning between steps and describe patient demographics and clinical characteristics per group. Overall, 647,308 patients with asthma were identified (40,096 aged 5-11 years; 607,212 aged 12-80 years). Most treated patients were in step 1 or 2 (88.3% of children/67.5% of adults in December 2007; 83.0% of children/67.0% of adults in June 2016). Most patients remained within their treatment step within a 6-month interval (>78% of children and adults throughout the study duration). The proportion of patients stepping up and down reduced from the beginning of the study, although stepping down to step 1 was relatively common in both adults and children. Few patients had a recorded asthma review in the year before reference date (18.8% of children and 14.8% of adults). Although prescribing patterns meant that most patients remained within their treatment step throughout the study, we cannot be sure that this was because their disease was truly stable. The small proportion of patients stepping up/down and the lack of recorded asthma review suggest that patients may not be treated in accordance with BTS/SIGN guidelines.
Identifiants
pubmed: 31296867
doi: 10.1038/s41533-019-0137-7
pii: 10.1038/s41533-019-0137-7
pmc: PMC6624291
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Références
Arch Dis Child. 2012 Jun;97(6):521-5
pubmed: 21596728
Arch Dis Child. 2007 Oct;92(10):847-9
pubmed: 17785369
Arch Dis Child. 2009 Jan;94(1):16-22
pubmed: 18701558
Eur Respir J. 1999 Sep;14(3):605-9
pubmed: 10543282
BMC Pulm Med. 2010 May 14;10:29
pubmed: 20470409
J Asthma. 1999 Jun;36(4):381-7
pubmed: 10386502
Breathe (Sheff). 2015 Mar;11(1):14-24
pubmed: 26306100
Eur Respir J. 2018 Jun 28;51(6):
pubmed: 29773688
BMJ Open. 2017 Aug 11;7(8):e017474
pubmed: 28801439
BMC Med. 2017 Jan 27;15(1):18
pubmed: 28126029
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Prim Care Respir J. 2013 Sep;22(3):290-5
pubmed: 23797678
BMJ. 2017 Oct 16;359:j4438
pubmed: 29038166
BMC Med. 2016 Aug 29;14(1):113
pubmed: 27568881
Thorax. 2018 Apr;73(4):313-320
pubmed: 29074814